Method of treating cancer or a blood disorder
OwnerQuteba EBRAHEMinventor
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method of treating cancer or a blood disorder disease in a patient, the method comprising administering a therapeutically effective amount of a combination of compounds comprising (1) a hypomethylating agent (HMA) and (2) an XPO1 inhibitor to a patient. The XPO1 inhibitor can be Valtrate or Caffeic acid phenyl ester (CAPE) or salt, hydrate or derivative thereof. Cancers that may be treated with this method include acute myeloid leukemia (AML) particularly leukemias in which a MLL mutation is present or one or both of an NPM1 mutation and an FLT3 mutation is present.
Claims19
A method of treating cancer or a blood disorder in a patient, the method comprising administering a therapeutically effective amount of a combination comprising (1) a hypomethylating agent (HMA) and (2) a compound selected from Valtrate or a derivative thereof and Caffeic acid phenethyl ester (CAPE) or a derivative thereof, and the pharmaceutically acceptable salts and hydrates of any of the foregoing to the patient.
The method of claim 13, wherein an additional active compound is administered and the additional active compound is daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin, docetaxel, paclitaxel, abraxane, taxotere, 5-fluorouracil, 6-mercaptopurine, capecitabine, cytarabine, gemcitabine, mechlorethamine, cyclophosphamide, chlorambucil, melphalan, ifosfamide, cisplatin, carboplatin, oxaliplatin, nedaplatin, vinblastine, vincristine, vindesine, vinorelbine, vincaminol, vineridine, or vinburnine.
A method of treating acute myeloid leukemia (AML) in a patient comprising administering a therapeutically effective amount of a combination of
- (1) a hypomethylating agent (HMA) and (2) an XPO1 inhibitor
- to the patient, wherein the patient is identified as having leukemia with either a MLL mutation or one or both of an NPM1 mutation and an FLT3 mutation.
A method of treating acute myeloid leukemia in a patient comprising determining that the patient has leukemia with either a MLL mutation or one or both of an NPM1 mutation and an FLT3 mutation and administering an effective amount of a combination of (1) a hypomethylating agent (HMA), (2) an XPO1 inhibitor, and optionally THU to the patient.
Dependencies are inferred from the claim text.